Annual Report 2003 Aventis - Sanofi

Aventis Strategic Brands
Lovenox / Clexane (enoxaparin sodium) is the most
widely studied and used low-molecular-weight heparin
(LMWH) in the world. It has been used to treat
an estimated 118 million patients in 96 countries
since it was fi rst introduced in 1987 and is approved
for more clinical indications than any other LMWH.
Approved indications
- Prophylaxis of deep vein thrombosis, which may
lead to pulmonary embolism
· in medical patients with severely restricted mobility
during acute illness
· in patients undergoing abdominal, hip or knee
replacement surgery
- Prophylaxis of ischemic complications of unstable
angina and non-Q-wave myocardial infarction,
when concurrently administered with aspirin
- Treatment of acute deep vein thrombosis
Major markets
Lovenox / Clexane is a market leader in all major
countries, including U.S., France, Germany, Italy,
Spain and UK.
Product features
- Approved for more indications than any other
anti-thrombin therapy
- Lovenox / Clexane with aspirin is more effective
than and as safe as unfractionated heparin in
reducing the incidence of death and myocardial
infarction in patients with unstable angina (UA)
and non-Q-wave myocardial infarction (NQMI)
>> 31